CIRM Clinical Trials

Through its strategic funding of clinical trials, CIRM helps advance innovative stem cell and gene therapy discoveries toward future treatments for patients.

CIRM funds clinical trials across a broad range of diseases and conditions that include rare and genetic disorders, treatment-resistant and refractory diseases, and many forms of cancer. Our involvement in the clinical trial process is vital to transforming potential treatments into available therapies by accelerating pathways to commercialization. Visit our Funding Opportunities page to apply for clinical trial research funding.

0

CIRM-Funded Clinical Trials

Disease AreasInvestigatorOrganizationPhaseTrial StatusTarget EnrollmentDetail
Brain Cancer Dr. Christine E. Brown City of Hope, Beckman Research Institute Phase 1 Active, not recruiting 82
Blood Cancer Dr. Edward Kavalerchik Angiocrine Bioscience, Inc. Phase 1 Completed 10
Leukemia, Acute Myeloid (AML) Mark Chao Forty Seven Inc. Phase 1 Closed 258
Melanoma
Skin cancer		 Dr. Antoni Ribas MD/PhD University of California, Los Angeles Phase 1 Closed 5
Spinal Cord Injury Dr. Jane Stephanie Lebkowski Dr. Geron Corporation Phase 1 Completed 5
Age-related macular degeneration Dr. Mark S Humayun University of Southern California Phase 1 Closed 16
Alpha Thalassemia Major Dr. Tippi C. MacKenzie University of California, San Francisco Phase 1 Enrolling by invitation 10
Pediatrics
Sickle Cell Disease		 Dr. Donald B. Kohn PhD University of California, Los Angeles Phase 1 Active, not recruiting 4
HIV/AIDS Prof. John A. Zaia City of Hope, Beckman Research Institute Phase 1 Active, not recruiting 12
Blood Cancer Thomas J Kipps University of California, San Diego Phase 1 Completed 26
Blood Cancer
Solid Tumors		 Professor Irving L Weissman MD Stanford University Phase 1 Completed 88
Solid Tumors Dr. Dennis J Slamon University of California, Los Angeles Phase 1 Completed 46
Kidney Failure Dr Robert Lowsky Stanford University Phase 1 Active, not recruiting 15
Arthritis
Osteoarthritis		 Dr. Kristen A Johnson Calibr Phase 1 Completed 60
Multiple Myeloma Rajesh Belani MD Poseida Therapeutics, Inc. Phase 1 Closed 105
Sickle Cell Disease Dr. De-Fu Zeng City of Hope, Beckman Research Institute Phase 1 Active, not recruiting 3
Severe Combined Immunodeficiency, Artemis deficient (ART-SCID) Mort Cowan University of California, San Francisco Phase 1 Recruiting 25
B cell cancers
Leukemia		 Dr. David B. Miklos Stanford University Phase 1 Active, not recruiting 56
Lung Cancer Dr. Steven M. Dubinett MD University of California, Los Angeles Phase 1 Active, not recruiting 24
Kidney Failure Dr. Everett H. Meyer Stanford University Phase 1 Recruiting 22
Sarcoma Theodore Scott Nowicki University of California, Los Angeles Phase 1 Closed 5
Brain Cancer
Breast Cancer		 Dr Saul J Priceman City of Hope, Beckman Research Institute Phase 1 Recruiting 39
Parkinson's Disease Krystof S. Bankiewicz Brain Neurotherapy Bio Phase 1 Active, not recruiting 11
Corneal Damage Dr. Sophie X Deng University of California, Los Angeles Phase 1 Recruiting 20
Retinitis Pigmentosa Clive Svendsen Cedars-Sinai Medical Center Phase 1 Recruiting 16
COVID-19
Respiratory Disorders		 Prof. John A. Zaia City of Hope, Beckman Research Institute Phase 1 Launching N/A
Sickle Cell Disease Dr Pierre Caudrelier ExCellThera Inc. Phase 1 Withdrawn N/A
Bone or Cartilage Disease Dr. Gayatri Rao Rocket Pharmaceuticals, Inc. Phase 1 Closed 1
Brain Cancer Dr. Leo D Wang City of Hope, Beckman Research Institute Phase 1 Recruiting 18
Leukemia, Acute Myeloid (AML) Joseph Paul Woodard Immune-Onc Therapeutics Phase 1 Recruiting 106
Amyotrophic Lateral Sclerosis Clive Svendsen Cedars-Sinai Medical Center Phase 1 Launching N/A
Sickle Cell Disease Mark C. Walters M.D. University of California, San Francisco Phase 1 Not yet recruiting 9
Stroke Dr. Gary Steinberg Stanford University Phase 1 Recruiting 30
Brain Cancer Crystal Mackall Stanford University Phase 1 Recruiting 54
B cell cancers
Leukemia
Leukemia, Acute Myeloid (AML)		 Dr. Matthew H Porteus Stanford University Phase 1 Recruiting 22
Heart failure Dr. Joseph C. Wu Stanford University Phase 1 Recruiting 18
IPEX Syndrome Dr. Rosa Bacchetta Stanford University Phase 1 Recruiting 30
Solid Tumors Dr. Pamela Reilly Contag BioEclipse Therapeutics INC. Phase 1 Recruiting 60
Epilepsy Dr. Cory R Nicholas Neurona Therapeutics Phase 1 Recruiting 40
Bladder or Urinary Tract Disorder James Yoo Wake Forest University Health Sciences Phase 1 Not yet recruiting 10
HIV/AIDS William Kennedy Excision BioTherapeutics Phase 1 Active, not recruiting 6
Brain Cancer Dr Jana Portnow City of Hope, Beckman Research Institute Phase 1 Launching N/A
Colon Cancer Ivan King Tachyon Therapeutics, Inc Phase 1 Launching N/A
Bone or Cartilage Disease
Hearing Loss
Intellectual Disability
Metabolic Disorders
Vision Loss		 Dr Robert Hayes Immusoft Corporation Phase 1 Launching N/A
Osteoarthritis Dr. Thomas W Chalberg Jr. Genascence Corporation Phase 1 Launching N/A
Anemia Ryotaro Nakamura City of Hope, Beckman Research Institute Phase 1 Launching N/A
HIV/AIDS Dr. Angelo Manuel Almeida Cardoso Ph.D., MD City of Hope, Beckman Research Institute Phase 1 Launching N/A
Leukemia, Acute Myeloid (AML) Elizabeth Budde City of Hope, Beckman Research Institute Phase 1 Launching N/A
Brain Cancer Dr. Reena Parada Thomas Stanford University Phase 1 Launching N/A
Melanoma Anusha Kalbasi Stanford University Phase 1 Launching N/A
Parkinson's Disease Dr. Edward Wirth III Aspen Neuroscience Phase 1 Launching N/A
Brain Cancer Dr. Hideho Okada University of California, San Francisco Phase 1 Launching N/A
Lupus, Systemic Lupus Erythematosus (SLE) Bob Valamehr Fate Therapeutics, Inc. Phase 1 Launching N/A
Brain Cancer Noriyuki Kasahara University of California, San Francisco Phase 1 Launching N/A
Solid Tumors Dr. John Le Gall Allogene Therapeutics Phase 1 Launching N/A
Leukemia, Acute Myeloid (AML) Rochelle Emery Senti Biosciences, Inc. Phase 1 Launching N/A
Blood Disorders Ilya Rachman MD PhD Nexcella, Inc. Phase 1 Launching N/A
Type 1 diabetes Howard Foyt ViaCyte, Inc. Phase 1/2 Closed 19
B cell cancers
Leukemia		 Thomas J Kipps University of California, San Diego Phase 1/2 Active, not recruiting 102
Type 1 diabetes Manasi Jaiman ViaCyte, Inc. Phase 1/2 Completed 49
Huntington's Disease Dr. Vicki Wheelock University of California, Davis Phase 1/2 Completed 29
Spinal Cord Injury Francois Binette Lineage Cell Therapeutics, Inc. Phase 1/2 Completed 25
Amyotrophic Lateral Sclerosis Professor Clive Niels Svendsen Cedars-Sinai Medical Center Phase 1/2 Completed 18
Retinitis Pigmentosa Dr. Henry John Klassen University of California, Irvine Phase 1/2 Completed 28
Immune Disease
Pediatrics
X-linked Chronic Granulomatous Disease		 Dr. Donald B. Kohn PhD University of California, Los Angeles Phase 1/2 Recruiting 16
Immune Disease
Severe Combined Immunodeficiency, X-linked (X-SCID)		 Stephen Gottschalk St. Jude Children’s Research Hospital Phase 1/2 Suspended 28
Immune Disease
Pediatrics
Severe Combined Immunodeficiency, X-linked (X-SCID)		 Dr. Judith A Shizuru
Wendy Pang		 Stanford University
Jasper Therapeutics, Inc.		 Phase 1/2 Recruiting 40
HIV/AIDS Geoff Symonds Calimmune, Inc. Phase 1/2 Completed 13
HIV-related Lymphoma
HIV/AIDS		 Dr Mehrdad Abedi University of California, Davis Phase 1/2 Active, not recruiting 11
Colon Cancer Mark Chao Forty Seven Inc. Phase 1/2 Completed 78
Osteonecrosis Nancy E. Lane University of California, Davis Phase 1/2 Completed 58
Pulmonary Hypertension
Vascular Disease		 Dr. Michael I Lewis Cedars-Sinai Medical Center Phase 1/2 Completed 26
Blood Cancer
Bone Marrow Transplant and Viral Infection		 Michael A. Pulsipher Children’s Hospital of Los Angeles Phase 1/2 Active, not recruiting 60
Beta Thalassemia Bettina Cockroft Sangamo BioSciences, Inc. Phase 1/2 Completed 5
Immune Disease
Leukocyte Adhesion Deficiency		 Dr. Kinnari Patel Rocket Pharmaceuticals, Inc. Phase 1/2 Completed 9
Type 1 diabetes Peter Stock University of California, San Francisco Phase 1/2 Recruiting 8
Cystinosis
Kidney Failure		 Dr. Stephanie Cherqui University of California, San Diego Phase 1/2 Active, not recruiting 6
COVID-19
Respiratory Disorders		 William van der Touw Celularity Inc. Phase 1/2 Closed 86
HIV/AIDS
Immune Disease		 Steven G. Deeks University of California, San Francisco Phase 1/2 Recruiting 18
Muscle Injury Peter C Belafsky University of California, Davis Phase 1/2 Recruiting 62
Anemia
Bone Marrow Transplant and Viral Infection		 Alice Bertaina Stanford University Phase 1/2 Launching N/A
Anemia Dr. Matthew H Porteus Stanford University Phase 1/2 Launching N/A
Solid Tumors Pei Wang Eureka Therapeutics, Inc. Phase 1/2 Launching N/A
Neurological Disorders
Other		 Prof. Olivia Kim-McManus University of California, San Diego Phase 1/2 Launching N/A
Immune Disease DR Jonathan Benjamin ImmPACT-Bio, Inc. Phase 1/2 Launching N/A
Age-related macular degeneration Dr. Jeffrey H Stern Luxa Biotechnology Phase 1/2 Launching N/A
Blood Cancer Dr. Edward Kavalerchik Angiocrine Bioscience, Inc. Phase 1/2 Completed 42
Developmental Disorders
Spina Bifida		 Dr. Diana L. Farmer University of California, Davis Phase 2 Recruiting 55
Leukemia, Acute Myeloid (AML) Dr. Colleen Delaney Nohla Therapeutics Inc Phase 2 Closed 146
Stroke Dr. Bijan Nejadnik SanBio, Inc. Phase 2 Completed 163
Retinitis Pigmentosa Henry John Klassen jCyte, Inc Phase 2 Completed 84
Genetic Disorder
Immune Disease
Pediatrics
Severe Combined Immunodeficiency, Adenosine deaminase-deficient (ADA-SCID)		 Dr. Donald B Kohn
Leslie Meltzer
Dr. Donald B. Kohn PhD		 University of California, Los Angeles
Orchard Therapeutics plc		 Phase 2 Completed 10
Heart failure Dr. Rachel Ruckdeschel Smith Capricor, Inc Phase 2 Closed 135
Type 1 diabetes Dr. William Sietsema Caladrius Biosciences Phase 2 Completed 113
Heart disease associated with Duchenne muscular dystrophy Dr. Linda Marban Capricor, Inc Phase 2 Completed 25
Retinitis Pigmentosa Henry John Klassen jCyte, Inc Phase 2 Completed 84
COVID-19 Dr. Michael Matthay MD University of California, San Francisco Phase 2 Completed 120
Sickle Cell Disease David Williams Boston Children’s Hospital Phase 2 Recruiting 25
Corneal Damage R. Kim Brazzell Combangio, Inc. Phase 2 Launching N/A
Age-related macular degeneration Dr Jane S Lebkowski Regenerative Patch Technologies LLC Phase 2 Launching N/A
Neurological Disorders Amit Etkin Alto Neuroscience Phase 2 Launching N/A
Danon Disease
Pediatrics		 Dr. Jonathan Schwartz Rocket Pharmaceuticals, Inc. Phase 2 Launching N/A
Kidney Failure Jeffrey Lawson Humacyte, Inc. Phase 3 Active, not recruiting 240
Melanoma Robert Dillman Caladrius Biosciences Phase 3 Closed 4
Amyotrophic Lateral Sclerosis Dr. Ralph Kern BrainStorm Cell Therapeutics Phase 3 Completed 196
Brain Cancer Anthony J. Gringeri ImmunoCellular Therapeutics Phase 3 Suspended 234
Kidney Failure Jeffrey Lawson Humacyte, Inc. Phase 3 Completed 355
Kidney Failure Daniel Brennan Medeor Acquisition Corp. Phase 3 Completed 30
B cell cancers Dr. Paul Finnegan Angiocrine Bioscience, Inc. Phase 3 Closed 130